220 related articles for article (PubMed ID: 1574031)
1. Methylated catecholamine metabolites for diagnosis of neuroblastoma.
Candito M; Thyss A; Albertini M; Deville A; Politano S; Mariani R; Chambon P
Med Pediatr Oncol; 1992; 20(3):215-20. PubMed ID: 1574031
[TBL] [Abstract][Full Text] [Related]
2. [Sensitivity and specificity of the determination of urinary catecholamines and their acid metabolites in the diagnosis of neuroblastoma in children].
Horsmans Y; Desager JP; Harvengt C
Bull Cancer; 1990; 77(10):985-9. PubMed ID: 2249018
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of methylated catecholamine metabolites in a child with neuroblastoma maturing into ganglioneuroma.
Candito M; Soler C; Deville A; Bekri S; Chambon P; Thyss A
Med Pediatr Oncol; 1996 Jan; 26(1):57-60. PubMed ID: 7494513
[TBL] [Abstract][Full Text] [Related]
4. Age-related medical decision limits for urinary free (unconjugated) metadrenalines, catecholamines and metabolites in random urine specimens from children.
Davidson DF; Hammond PJ; Murphy D; Carachi R
Ann Clin Biochem; 2011 Jul; 48(Pt 4):358-66. PubMed ID: 21670092
[TBL] [Abstract][Full Text] [Related]
5. Age-related changes in catecholamine metabolites of human urine from birth to adulthood.
Dalmaz Y; Peyrin L; Sann L; Dutruge J
J Neural Transm; 1979; 46(2):153-74. PubMed ID: 512651
[TBL] [Abstract][Full Text] [Related]
6. Changes in urinary excretion of catecholamines and their metabolites in pediatric dental patients.
Sakuma N; Nagasaka N
ASDC J Dent Child; 1996; 63(2):118-22. PubMed ID: 8708120
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers.
Lam L; Woollard GA; Teague L; Davidson JS
Ann Clin Biochem; 2017 Mar; 54(2):264-272. PubMed ID: 27235704
[TBL] [Abstract][Full Text] [Related]
8. Day-to-day intraindividual reliability and interindividual differences in monoamines excretion.
Curtin F; Walker JP; Schulz P
J Affect Disord; 1996 Jun; 38(2-3):173-8. PubMed ID: 8791186
[TBL] [Abstract][Full Text] [Related]
9. Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients.
Verly IR; van Kuilenburg AB; Abeling NG; Goorden SM; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GL; Merks JH; Caron HN; Tytgat GA
Eur J Cancer; 2017 Feb; 72():235-243. PubMed ID: 28061374
[TBL] [Abstract][Full Text] [Related]
10. Optimising urinary catecholamine metabolite diagnostics for neuroblastoma.
Matser YAH; Verly IRN; van der Ham M; de Sain-van der Velden MGM; Verhoeven-Duif NM; Ash S; Cangemi G; Barco S; Popovic MB; van Kuilenburg ABP; Tytgat GAM;
Pediatr Blood Cancer; 2023 Jun; 70(6):e30289. PubMed ID: 37010353
[TBL] [Abstract][Full Text] [Related]
11. [Qualitative analysis of the main urinary metabolites of dopamine, epinephrine and norepinephrine by gas chromatography].
Bègue RJ; Bazerolle O; Desgres J; Lallemant C; Padieu P
Pathol Biol (Paris); 1971; 19(15):719-25. PubMed ID: 4942503
[No Abstract] [Full Text] [Related]
12. Catecholamine measurements in pheochromocytoma and neuroblastoma.
Spiegel HE
Ann Clin Lab Sci; 1974; 4(3):174-7. PubMed ID: 4363482
[No Abstract] [Full Text] [Related]
13. Biochemical testing for neuroblastoma using plasma free 3-O-methyldopa, 3-methoxytyramine, and normetanephrine.
Peitzsch M; Butch ER; Lovorn E; Mangelis A; Furman WL; Santana VM; Hero B; Berthold F; Shulkin BL; Huebner A; Eisenhofer G
Pediatr Blood Cancer; 2020 Feb; 67(2):e28081. PubMed ID: 31724812
[TBL] [Abstract][Full Text] [Related]
14. High correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates.
Linnoila M; Oliver J; Adinoff B; Potter WZ
Arch Gen Psychiatry; 1988 Aug; 45(8):701-4. PubMed ID: 3395200
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a paediatric age-related reference interval for the measurement of urinary total fractionated metanephrines.
Griffin A; O'Shea P; FitzGerald R; O'Connor G; Tormey W
Ann Clin Biochem; 2011 Jan; 48(Pt 1):41-4. PubMed ID: 21123298
[TBL] [Abstract][Full Text] [Related]
16. Iron deficiency anemia and increased urinary norepinephrine excretion.
Voorhess ML; Stuart MJ; Stockman JA; Oski FA
J Pediatr; 1975 Apr; 86(4):542-7. PubMed ID: 1127500
[TBL] [Abstract][Full Text] [Related]
17. Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations.
Amano H; Uchida H; Harada K; Narita A; Fumino S; Yamada Y; Kumano S; Abe M; Ishigaki T; Sakairi M; Shirota C; Tainaka T; Sumida W; Yokota K; Makita S; Karakawa S; Mitani Y; Matsumoto S; Tomioka Y; Muramatsu H; Nishio N; Osawa T; Taguri M; Koh K; Tajiri T; Kato M; Matsumoto K; Takahashi Y; Hinoki A
Cancer Sci; 2024 May; 115(5):1634-1645. PubMed ID: 38411285
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients.
Strenger V; Kerbl R; Dornbusch HJ; Ladenstein R; Ambros PF; Ambros IM; Urban C
Pediatr Blood Cancer; 2007 May; 48(5):504-9. PubMed ID: 16732582
[TBL] [Abstract][Full Text] [Related]
19. Metabolic adrenergic changes during submaximal exercise and in the recovery period in man.
Pequignot JM; Peyrin L; Mayet MH; Flandrois R
J Appl Physiol Respir Environ Exerc Physiol; 1979 Oct; 47(4):701-5. PubMed ID: 511676
[TBL] [Abstract][Full Text] [Related]
20. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Eisenhofer G; Brown S; Peitzsch M; Pelzel D; Lattke P; Glöckner S; Stell A; Prejbisz A; Fassnacht M; Beuschlein F; Januszewicz A; Siegert G; Reichmann H
Ann Clin Biochem; 2014 Jan; 51(Pt 1):38-46. PubMed ID: 23873873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
